Selexys Pharmaceuticals Corporation

Although the US FDA has been largely able keep up its review functions throughout the government shutdown so far, it remained a quiet week of drug development announcements. Here's your news in brief:

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging bioph

Emmaus Life Sciences Inc. envisages modest pricing of $11,000 to $18,000 yearly for Endari , which is a breakthrough in terms of being the first drug approved for sickle cell disease in almost 20 y

Novartis AG says its investments in innovative growth drivers are paying off and should lead to resumed sales growth next year - but don't expect the Swiss group to make a big acquisition to help ac